China CAS:35380-71-3 Manufacturer

We hold strengthening and perfecting our items and repair. At the same time, we get the job done actively to do research and progress for CAS:35380-71-3, We welcome new and aged buyers from all walks of lifetime to make contact with us for potential small business associations and mutual success!
CAS:35380-71-3, Our company warmly invites domestic and overseas customers to come and negotiate business with us. Let us join hands to create a brilliant tomorrow! We're looking forward to cooperating with you sincerely to achieve a win-win situation. We promise to try our best to supply you with high quality and efficient services.

Hot Products

  • Budesonide

    Budesonide

    Budesonide has USP, EP specifications. CEP, GMP and FDA approved.

    CAS:51333-22-3

  • 21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione

    21-Acetoxy-11β-hydroxypregna-1,4,16-triene-3,20-dione is an intermediate in the synthesis of Budesonide (B689490) related derivatives.

    CAS:3044-42-6

  • Oxcarbazepine

    Oxcarbazepine

    Oxcarbazepine has CP, EP and USP specifications. CEP and DMF available, GMP approved.

    CAS:28721-07-5

  • Mifepristone Tablets 25mg*6

    Mifepristone Tablets 25mg*6

    Mifepristone Tablets 25mg*6
    Indications:Abortion
  • 16alpha-Hydroxyprednisolone Acetate

    16alpha-Hydroxyprednisolone Acetate

    16alpha-Hydroxyprednisolone Acetate is used to observe interaction of some steroid drugs with β-cyclodextrin polymer to calculate the relative strengh of interaction between the hydrophobicity parameters of the drugs and the strenght of the drug-β-​cyclodextrin polymer.

    CAS:86401-80-1

  • Flumethasone

    Flumethasone

    Flumethasone is a glucocorticoid, an anti-inflammatory. It can promptly decrease inflammation, exudation and itching is experienced after application.

    CAS:2135-17-3

Send Inquiry

X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept